questionsmedicales.fr
Composés hétérocycliques
Composés hétérocycliques à cycles fusionnés
Composés hétérobicycliques
Benzopyranes
Coumarines
4-Hydroxycoumarines
4-Hydroxycoumarines : Questions médicales fréquentes
Termes MeSH sélectionnés :
Molecular Docking Simulation
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "4-Hydroxycoumarines : Questions médicales les plus fréquentes",
"headline": "4-Hydroxycoumarines : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les 4-Hydroxycoumarines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-10",
"dateModified": "2025-04-04",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "4-Hydroxycoumarines"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Coumarines",
"url": "https://questionsmedicales.fr/mesh/D003374",
"about": {
"@type": "MedicalCondition",
"name": "Coumarines",
"code": {
"@type": "MedicalCode",
"code": "D003374",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.150.446"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Acénocoumarol",
"alternateName": "Acenocoumarol",
"url": "https://questionsmedicales.fr/mesh/D000074",
"about": {
"@type": "MedicalCondition",
"name": "Acénocoumarol",
"code": {
"@type": "MedicalCode",
"code": "D000074",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.150.446.520.079"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Dicoumarol",
"alternateName": "Dicumarol",
"url": "https://questionsmedicales.fr/mesh/D001728",
"about": {
"@type": "MedicalCondition",
"name": "Dicoumarol",
"code": {
"@type": "MedicalCode",
"code": "D001728",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.150.446.520.203"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Biscoumacétate d'éthyle",
"alternateName": "Ethyl Biscoumacetate",
"url": "https://questionsmedicales.fr/mesh/D005017",
"about": {
"@type": "MedicalCondition",
"name": "Biscoumacétate d'éthyle",
"code": {
"@type": "MedicalCode",
"code": "D005017",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.150.446.520.451"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Phenprocoumone",
"alternateName": "Phenprocoumon",
"url": "https://questionsmedicales.fr/mesh/D010644",
"about": {
"@type": "MedicalCondition",
"name": "Phenprocoumone",
"code": {
"@type": "MedicalCode",
"code": "D010644",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.150.446.520.750"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Warfarine",
"alternateName": "Warfarin",
"url": "https://questionsmedicales.fr/mesh/D014859",
"about": {
"@type": "MedicalCondition",
"name": "Warfarine",
"code": {
"@type": "MedicalCode",
"code": "D014859",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.150.446.520.914"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "4-Hydroxycoumarines",
"alternateName": "4-Hydroxycoumarins",
"code": {
"@type": "MedicalCode",
"code": "D015110",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Li Sheng",
"url": "https://questionsmedicales.fr/author/Li%20Sheng",
"affiliation": {
"@type": "Organization",
"name": "Department of Drug Metabolism, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China."
}
},
{
"@type": "Person",
"name": "Zahra Hosseini-Khah",
"url": "https://questionsmedicales.fr/author/Zahra%20Hosseini-Khah",
"affiliation": {
"@type": "Organization",
"name": "Diabetes Research Center, Mazandaran University of Medical Sciences, Sari, Iran."
}
},
{
"@type": "Person",
"name": "Saeed Emami",
"url": "https://questionsmedicales.fr/author/Saeed%20Emami",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicinal Chemistry and Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran. sdemami12@gmail.com."
}
},
{
"@type": "Person",
"name": "Jhonnathan Brawley",
"url": "https://questionsmedicales.fr/author/Jhonnathan%20Brawley",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, University of Nevada, Reno, Nevada 89557-0216, United States."
}
},
{
"@type": "Person",
"name": "Amarawan Intasiri",
"url": "https://questionsmedicales.fr/author/Amarawan%20Intasiri",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, University of Nevada, Reno, Nevada 89557-0216, United States."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Molecular docking, simulation and binding free energy analysis of small molecules as PfHT1 inhibitors.",
"datePublished": "2022-08-26",
"url": "https://questionsmedicales.fr/article/36026508",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0268269"
}
},
{
"@type": "ScholarlyArticle",
"name": "Py-CoMFA, docking, and molecular dynamics simulations of Leishmania (L.) amazonensis arginase inhibitors.",
"datePublished": "2024-05-21",
"url": "https://questionsmedicales.fr/article/38773273",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-62520-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Exploring the molecular mechanism of ginseng against anthracycline-induced cardiotoxicity based on network pharmacology, molecular docking and molecular dynamics simulation.",
"datePublished": "2024-09-06",
"url": "https://questionsmedicales.fr/article/39243097",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s41065-024-00334-y"
}
},
{
"@type": "ScholarlyArticle",
"name": "Study of the antidiabetic mechanism of berberine compound on FOXO1 transcription factor through molecular docking and molecular dynamics simulations.",
"datePublished": "2024-07-09",
"url": "https://questionsmedicales.fr/article/38981921",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00894-024-06060-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "Research advances of molecular docking and molecular dynamic simulation in recognizing interaction between muscle proteins and exogenous additives.",
"datePublished": "2023-07-08",
"url": "https://questionsmedicales.fr/article/37453331",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.foodchem.2023.136836"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétérocycliques à cycles fusionnés",
"item": "https://questionsmedicales.fr/mesh/D000072471"
},
{
"@type": "ListItem",
"position": 4,
"name": "Composés hétérobicycliques",
"item": "https://questionsmedicales.fr/mesh/D006574"
},
{
"@type": "ListItem",
"position": 5,
"name": "Benzopyranes",
"item": "https://questionsmedicales.fr/mesh/D001578"
},
{
"@type": "ListItem",
"position": 6,
"name": "Coumarines",
"item": "https://questionsmedicales.fr/mesh/D003374"
},
{
"@type": "ListItem",
"position": 7,
"name": "4-Hydroxycoumarines",
"item": "https://questionsmedicales.fr/mesh/D015110"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : 4-Hydroxycoumarines - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur 4-Hydroxycoumarines",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-05",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur 4-Hydroxycoumarines",
"description": "Comment diagnostiquer une surdose de 4-hydroxycoumarines ?\nQuels tests sont utilisés pour surveiller le traitement par 4-hydroxycoumarines ?\nQuels symptômes indiquent une complication du traitement ?\nComment évaluer l'efficacité des 4-hydroxycoumarines ?\nQuels signes cliniques nécessitent une évaluation urgente ?",
"url": "https://questionsmedicales.fr/mesh/D015110?mesh_terms=Molecular+Docking+Simulation&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur 4-Hydroxycoumarines",
"description": "Quels sont les effets secondaires courants des 4-hydroxycoumarines ?\nComment reconnaître une réaction allergique aux 4-hydroxycoumarines ?\nQuels symptômes peuvent indiquer une thrombose malgré le traitement ?\nQuels signes indiquent une surdose de 4-hydroxycoumarines ?\nQuels symptômes nécessitent un ajustement de la dose ?",
"url": "https://questionsmedicales.fr/mesh/D015110?mesh_terms=Molecular+Docking+Simulation&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur 4-Hydroxycoumarines",
"description": "Comment prévenir les complications des 4-hydroxycoumarines ?\nQuelles précautions prendre lors de l'utilisation de 4-hydroxycoumarines ?\nComment éduquer les patients sur les 4-hydroxycoumarines ?\nQuels aliments éviter avec les 4-hydroxycoumarines ?\nComment gérer les interactions médicamenteuses ?",
"url": "https://questionsmedicales.fr/mesh/D015110?mesh_terms=Molecular+Docking+Simulation&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur 4-Hydroxycoumarines",
"description": "Comment traiter une surdose de 4-hydroxycoumarines ?\nQuels médicaments interagissent avec les 4-hydroxycoumarines ?\nQuelle est l'alternative aux 4-hydroxycoumarines ?\nComment ajuster la dose de 4-hydroxycoumarines ?\nQuels sont les traitements de soutien lors d'une surdose ?",
"url": "https://questionsmedicales.fr/mesh/D015110?mesh_terms=Molecular+Docking+Simulation&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur 4-Hydroxycoumarines",
"description": "Quelles sont les complications possibles des 4-hydroxycoumarines ?\nComment gérer une hémorragie due aux 4-hydroxycoumarines ?\nQuels facteurs augmentent le risque de complications ?\nComment prévenir les thromboses sous traitement ?\nQuels signes indiquent une complication grave ?",
"url": "https://questionsmedicales.fr/mesh/D015110?mesh_terms=Molecular+Docking+Simulation&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur 4-Hydroxycoumarines",
"description": "Quels sont les facteurs de risque pour les complications des 4-hydroxycoumarines ?\nComment l'alimentation influence-t-elle l'efficacité des 4-hydroxycoumarines ?\nQuels médicaments augmentent le risque de saignement ?\nComment l'âge affecte-t-il le traitement par 4-hydroxycoumarines ?\nQuels antécédents médicaux sont préoccupants ?",
"url": "https://questionsmedicales.fr/mesh/D015110?mesh_terms=Molecular+Docking+Simulation&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une surdose de 4-hydroxycoumarines ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests de coagulation et l'évaluation des symptômes cliniques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour surveiller le traitement par 4-hydroxycoumarines ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le temps de prothrombine (TP) et l'INR sont les tests principaux pour surveiller l'efficacité."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une complication du traitement ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des saignements inhabituels, des ecchymoses ou des douleurs abdominales peuvent indiquer une complication."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité des 4-hydroxycoumarines ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est évaluée par la réduction des événements thromboemboliques et les résultats des tests de coagulation."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques nécessitent une évaluation urgente ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes de saignement grave, comme des hémorragies cérébrales ou gastro-intestinales, nécessitent une évaluation urgente."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires courants des 4-hydroxycoumarines ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent des saignements, des nausées et des douleurs abdominales."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une réaction allergique aux 4-hydroxycoumarines ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées, des démangeaisons ou un gonflement peuvent indiquer une réaction allergique."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer une thrombose malgré le traitement ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs, un gonflement ou une rougeur dans une jambe peuvent indiquer une thrombose persistante."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une surdose de 4-hydroxycoumarines ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des saignements excessifs, des ecchymoses et des douleurs abdominales peuvent indiquer une surdose."
}
},
{
"@type": "Question",
"name": "Quels symptômes nécessitent un ajustement de la dose ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des saignements fréquents ou des résultats d'INR élevés peuvent nécessiter un ajustement de la dose."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications des 4-hydroxycoumarines ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surveillance régulière de l'INR et une éducation des patients sont essentielles pour prévenir les complications."
}
},
{
"@type": "Question",
"name": "Quelles précautions prendre lors de l'utilisation de 4-hydroxycoumarines ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les activités à risque de blessure et informer les professionnels de santé de l'utilisation."
}
},
{
"@type": "Question",
"name": "Comment éduquer les patients sur les 4-hydroxycoumarines ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Informer sur les effets secondaires, l'importance des tests de coagulation et les signes d'alerte."
}
},
{
"@type": "Question",
"name": "Quels aliments éviter avec les 4-hydroxycoumarines ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les aliments riches en vitamine K, comme les légumes à feuilles vertes, pour maintenir l'efficacité."
}
},
{
"@type": "Question",
"name": "Comment gérer les interactions médicamenteuses ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Consulter un professionnel de santé avant de prendre d'autres médicaments pour éviter les interactions."
}
},
{
"@type": "Question",
"name": "Comment traiter une surdose de 4-hydroxycoumarines ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut l'administration de vitamine K et la surveillance des paramètres de coagulation."
}
},
{
"@type": "Question",
"name": "Quels médicaments interagissent avec les 4-hydroxycoumarines ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antibiotiques, des anti-inflammatoires et certains antifongiques peuvent interagir avec ces anticoagulants."
}
},
{
"@type": "Question",
"name": "Quelle est l'alternative aux 4-hydroxycoumarines ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anticoagulants directs comme le rivaroxaban ou l'apixaban sont des alternatives possibles."
}
},
{
"@type": "Question",
"name": "Comment ajuster la dose de 4-hydroxycoumarines ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La dose est ajustée en fonction des résultats de l'INR et des facteurs de risque individuels."
}
},
{
"@type": "Question",
"name": "Quels sont les traitements de soutien lors d'une surdose ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des transfusions de plaquettes et des soins intensifs peuvent être nécessaires en cas de surdose sévère."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles des 4-hydroxycoumarines ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des hémorragies, des thromboses et des réactions allergiques."
}
},
{
"@type": "Question",
"name": "Comment gérer une hémorragie due aux 4-hydroxycoumarines ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion inclut l'arrêt du médicament, l'administration de vitamine K et des soins médicaux appropriés."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de complications ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge avancé, les maladies hépatiques et l'utilisation concomitante d'autres anticoagulants augmentent le risque."
}
},
{
"@type": "Question",
"name": "Comment prévenir les thromboses sous traitement ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir un suivi régulier et ajuster la dose en fonction des résultats de l'INR pour prévenir les thromboses."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une complication grave ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs thoraciques, des difficultés respiratoires ou des saignements importants indiquent une complication grave."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les complications des 4-hydroxycoumarines ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents de thrombose, l'âge avancé et les maladies hépatiques sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "Comment l'alimentation influence-t-elle l'efficacité des 4-hydroxycoumarines ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en vitamine K peut réduire l'efficacité des 4-hydroxycoumarines."
}
},
{
"@type": "Question",
"name": "Quels médicaments augmentent le risque de saignement ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anti-inflammatoires non stéroïdiens (AINS) et certains antibiotiques peuvent augmenter le risque de saignement."
}
},
{
"@type": "Question",
"name": "Comment l'âge affecte-t-il le traitement par 4-hydroxycoumarines ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes âgées peuvent avoir une sensibilité accrue et nécessiter un ajustement de la dose."
}
},
{
"@type": "Question",
"name": "Quels antécédents médicaux sont préoccupants ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents de maladies hépatiques ou de troubles de la coagulation sont préoccupants lors du traitement."
}
}
]
}
]
}
Antimalarial drug resistance has thrown a spanner in the works of malaria elimination. New drugs are required for ancillary support of existing malaria control efforts. Plasmodium falciparum requires ...
Leishmaniasis is a disease caused by a protozoan of the genus Leishmania, affecting millions of people, mainly in tropical countries, due to poor social conditions and low economic development. First-...
Previous clinical and basic studies have revealed that ginseng might have cardioprotective properties against anthracycline-induced cardiotoxicity (AIC). However, the underlying mechanism of ginseng a...
Fourteen drug-disease common targets were identified. Enrichment analysis showed that the AGE-RAGE in diabetic complications, fluid shear stress and atherosclerosis, and TNF signaling pathway were pot...
This study suggested that ginseng might exert their protective effects against AIC through the derived effector compounds beta-Sitosterol, Kaempferol and Fumarine by targeting CCNA2, STAT1, and ICAM1,...
Diabetes mellitus (DM) is a metabolic disorder disease that causes hyperglycemia conditions and associated with various chronic complications leading to mortality. Due to high toxicity of conventional...
Docking between ligand and FOXO1 receptor was carried out with Autodock4.2. For molecular dynamics simulations, the force fields of DNA.OL15, protein.ff14SB, gaff2, and tip3p were used....
During storage and processing, muscle proteins, e.g. myosin and myoglobin, will inevitably undergo degeneration, which is thus accompanied by quality deterioration of muscle foods. Some exogenous addi...
Cereblon (CRBN) is a substrate receptor of E3 ubiquitin ligase as well as the target of thalidomide and lenalidomide, plays a vital role in endogenous protein degradation. In this article, two series ...
Direct oral anticoagulants are an important and relatively new class of synthetic anticoagulant drugs commonly used for the pharmacotherapy of thromboembolic disorders. However, they still have some l...
Cancer is a serious threat to human life and social development and the use of scientific methods for cancer prevention and control is necessary. In this study, HQSAR, CoMFA, CoMSIA and TopomerCoMFA m...
The pandemic of COVID-19 caused by SARS-CoV-2 has made a worldwide health emergency. Despite the fact that current vaccines are readily available, several SARSCoV-2 variants affecting the existing vac...
Oritavancin is a semi-synthetic lipoglycopeptide antibiotic primarily used to treat serious infections caused by Gram-positive bacteria. The aim of this study was to elucidate possible molecular targe...
Computational methods were used in this study which include target prediction, molecular docking, molecular dynamics simulation, pharmacokinetics prediction, and physiological-based pharmacokinetics (...
Oritavancin was moderately soluble in water and did not permeate the blood-brain barrier. Seven molecular targets were identified in humans. Molecular docking results showed highest binding affinity o...
This comprehensive computational study has provided invaluable insights into the pharmacological profile of Oritavancin, aiding its further development and optimization for clinical use....